CONTACT INFORMATION Contact Name: Dr George Frodsham E-mail: george@medisieve.co.uk Website: www.medisieve.com Funding required: £4,000,000
THE SOLUTION MediSieve’s Magnetic Blood Filtration (MBF) is a groundbreaking innovation, offering precision in disease management and therapy enhancement. This technology selectively removes or isolates specific substances from the bloodstream, like pathogens, antibodies, and cells. Effective in a wide range of conditions, including inflammation, oncology, and autoimmune disorders, it allows targeted treatment, significantly outperforming broad- spectrum methods. The platform consists of the Capture System (Filter and Magnet) and Magnetic Beads. The Beads, magnetic particles engineered to bind specific clinical targets, are introduced into circulating blood via an extracorporeal circuit. This blood then passes through the MediSieve Filter, housed within the Magnet, capturing the Beads and their bound targets, preventing their re-entry into the patient. The use of beads and their capability to target virtually any substance depending on the surface ligand enables the technology’s application across a wide range of clinical scenarios. The impact of MBF technology is particularly significant in the field of AAV gene therapies. By extracting neutralising antibodies, MediSieve’s technology addresses pre-existing immunity, doubling the pool of eligible patients and enabling redosing for long-term treatment success. Furthermore, MBF holds the potential to revolutionise medical research and therapeutic practices by providing a means to efficiently isolate valuable substances from the blood for diagnostic and research purposes. By selectively removing and isolating substances from the blood, MediSieve’s technology fills a critical gap in medical treatment, aiming to enhance quality of life worldwide and advancing the precision and efficacy of clinical interventions and disease understanding.
ELEVATOR PITCH MediSieve uses advanced magnetic filtration to selectively remove or isolate blood substances, driving a paradigm shift in global healthcare. THE PROBLEM MediSieve is addressing the critical medical issues caused by the circulation of specific components in blood and the inability of current technologies to selectively target them. The bloodstream carries a variety of substances, including pathogens, cells, and antibodies, which can either cause diseases, hinder therapeutic treatments, or hold valuable information. This issue is particularly pronounced in Adeno- Associated Virus (AAV) Gene Therapies, MediSieve’s first use case. Neutralising antibodies (nAbs) in a patient’s bloodstream can block AAV capsids from reaching their intended targets, therefore compromising the effectiveness of the treatment. This makes approximately 880,000 people, or up to 60% of potential patients, ineligible for a therapy that often stands as the only treatment option for various rare diseases. The core challenge lies in the effective removal or isolation of these substances from blood. Traditional broad-spectrum methods are slow and non-specific, making them ineffective at achieving the necessary capture rates required to mitigate the issues these components pose. This highlights a significant gap in current medical practices, underscoring the pressing need for a targeted approach that MediSieve’s technology aims to fulfil.
Made with FlippingBook Learn more on our blog